Pandemic Flu Preparedness: A Manufacturing Perspective - Scalability, speed, and biosafety will be critical in the event of an influenza pandemic. The containment needs of an avian flu strain could pr

ADVERTISEMENT

Pandemic Flu Preparedness: A Manufacturing Perspective
Scalability, speed, and biosafety will be critical in the event of an influenza pandemic. The containment needs of an avian flu strain could present additional challenges.


BioPharm International


Conclusion

New funding as a result of the global pandemic influenza action plan to increase supply has spurred vaccine industry initiatives in planning manufacturing capacity. Given uncertain factors and the potential surge capacity requirement involved in the avian or pandemic influenza vaccine market, preparedness could come at a high cost. Although such a pre-emptive measure is the right step forward, a key question the vaccine manufacturing community must ask is "What production and facility concepts should be applied to provide a good business case?"

Aeby Thomas is a process engineer at NNE Pharmaplan, Søborg, Denmark, +45 4444 7777,
. At the same company, Niels Guldager is a specialist, business consulting services, and Klaus Hermansen is a senior specialist, business consulting services.

Suggested Reading

1. World Health Organization (WHO). Global pandemic influenza action to increase vaccine supply. Geneva, Switzerland: WHO Epidemic and Pandemic Alert Response (EPR) Publications; 2006 [cited July 1, 2007]. Available from: http://www.who.int/csr/resources/publications/influenza/CDS_EPR_GIP_2006_1.pdf.

2. World Health Organization (WHO). Working paper 1: Increasing production capacity for pandemic influenza vaccines. Draft doc., v. 4. Geneva, Switzerland: WHO Initiative for Vaccine Research (IVR); n.d. [cited July 1, 2007]. Available from: http://www.who.int/vaccine_research/diseases/influenza/Working_Paper_1.pdf.

3. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Influenza Vaccine Supply International Task Force (IVS ITF). R&D for avian/pandemic influenza vaccines. Geneva, Switzerland: IFPMA; 2006 October 17 [cited July 1, 2007]. Available from: http://www.ifpma.org/Influenza/content/pdfs/Table_Avian_Pandemic_Influenza_RnD_17Oct06.pdf

4. Rappouli R. Cell-culture based vaccine production: Technological options. The Bridge [serial online] 2006 Fall [cited July 1, 2007];36(3). Available from: http://www.nae.edu/nae/bridgecom.nsf/weblinks/MKEZ-6SZR4L?OpenDocument.

5. Galliher PM. Review of single-use technologies in biomanufacturing. Worcester Polytechnic Institute, Bioengineering Institute Symposium: New Developments in Biomanufacturing. 2007 Feb 20; Worcester, MA; 2007 [Cited July 1, 2007]. Available from: http://www.wpi.edu/Images/CMS/BEI/parrishgalliher.pdf.


blog comments powered by Disqus

ADVERTISEMENT

Moscow Hosts IFPMA Biosimilars Conference
May 17, 2013
AbbVie and Alvine Will Collaborate on Celiac Disease Therapy
May 15, 2013
FDA Issues Pharmacoepidemiologic Safety Study Guidance
May 14, 2013
USP Launches Initiative to Fight Counterfeit Drugs in Sub-Saharan Africa
May 13, 2013
Amgen Forms New Joint Venture to Commercialize Vectibix in China
May 13, 2013
Upcoming Conferences
UPCOMING CONFERENCES

Access Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA | July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA | August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA | August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA | August 20-21, 2013
Request Brochure

See All Conferences >>

ADVERTISEMENT

Author Guidelines
FindPharma
Source: BioPharm International,
Click here